MANCUSI, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 813
EU - Europa 594
AS - Asia 309
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.719
Nazione #
US - Stati Uniti d'America 813
IT - Italia 191
IE - Irlanda 148
SG - Singapore 134
HK - Hong Kong 87
CN - Cina 61
UA - Ucraina 57
FI - Finlandia 42
SE - Svezia 37
DE - Germania 31
RU - Federazione Russa 27
KR - Corea 15
NL - Olanda 13
CZ - Repubblica Ceca 11
GB - Regno Unito 10
BE - Belgio 7
CH - Svizzera 7
FR - Francia 3
IL - Israele 3
PL - Polonia 3
AT - Austria 2
AU - Australia 2
GR - Grecia 2
IN - India 2
LB - Libano 2
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
JO - Giordania 1
LT - Lituania 1
PT - Portogallo 1
SA - Arabia Saudita 1
TR - Turchia 1
TW - Taiwan 1
Totale 1.719
Città #
Chandler 162
Dublin 148
Singapore 108
Boardman 90
Hong Kong 87
San Mateo 87
Perugia 72
Santa Clara 52
Altamura 29
Medford 26
Princeton 26
Lawrence 24
Wilmington 24
Jacksonville 23
Andover 22
Beijing 22
Ann Arbor 15
Redmond 15
Seoul 15
Des Moines 12
Helsinki 12
Munich 12
Los Angeles 10
Norwalk 10
Houston 9
Saint Petersburg 9
Brno 8
Espoo 8
Florence 8
Groningen 8
West Jordan 8
Milan 7
Padova 7
Terni 7
Rome 6
Ancona 5
Ashburn 5
Brussels 5
Falls Church 5
Marsciano 5
Dallas 4
Deruta 4
Foligno 4
New York 4
Redwood City 4
San Paolo di Civitate 4
Shanghai 4
Amsterdam 3
Aurora 3
Bologna 3
Kiryat Ono 3
Nuremberg 3
Vigodarzere 3
Den Haag 2
Lappeenranta 2
London 2
Olomouc 2
Santarcangelo di Romagna 2
Venice 2
Woodbridge 2
Zaventem 2
Ahmedabad 1
Auburn Hills 1
Clifton 1
Dearborn 1
Frankfurt am Main 1
Grosseto 1
Izmir 1
Lisbon 1
Lonate Ceppino 1
Mirano 1
Moscow 1
Paris 1
Puyang Chengguanzhen 1
Rimini 1
Riyadh 1
San Diego 1
Taipei 1
Vienna 1
Zagreb 1
Totale 1.294
Nome #
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells 98
Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality 71
Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. 69
The effect of TNF-α on regulatory T cell function in graft-versus-host disease 69
Immunotherapy with alloreactive natural killer cells in haploidentical haematopoietic transplantation. 65
TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation 65
Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT. 64
Clinical impact of natural killer cell reconstitution after allogenic hematopoitic transplantation.Immunobiology working Party of the European Group for Blood and Marrow Transplantation 62
CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation 59
Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation. 55
T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease 55
Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. 52
New mechanism of lymphoma-induced bone marrow aplasia 51
Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. 49
Expansion of CD56-negative, CD16-positive, KIR-expressing natural killer cells after T cell-depleted haploidentical hematopoietic stem cell transplantation. 49
Deploying natural killer cell allotherapy in the setting of HLA-haplotype-mismatched hematopoietic stem cell transplantation 48
Enhancing Regulatory T Cell Function and Homing to the Gut to Improve graft-versus-host Disease Prevention after Adoptive Transfer in Allogeneic Hematopoietic Transplantation 47
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. 47
Natural killer cell allorecognition of missing self in allogenic hematopoietic transplantation :a tool for immunotherapy of leukemia. 46
Identifying NK alloreactive donors for haploidentical hematopoietic stem cell transplantation 46
Activation of Regulatory T Cells with IL-2 and TNF-alpha to Promote Homing to the Gut and to Improve Acute GvHD Prevention 45
Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. 45
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. 40
Natural killer-cell KIR repertoire reconstitution after haploidentical SCT. 40
Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. 39
Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. 39
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia 38
HLA-MATCHED TREG/TCON ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ENSURES REMARKABLE CHRONIC GVHD/LEUKEMIA FREE SURVIVAL IN HIGH-RISK LEUKEMIA PATIENTS 36
Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces non-relapse mortality 33
Acute GvHD after HLA- Haploidentical Hematopoietic Cell Transplantation with Regulatory and Conventional T Cell Immunotherapy Does Not Adversely Affect Transplantation Outcomes 30
HAPLOIDENTICAL TRANSPLANTATION WITH TREG-TCON ADOPTIVE IMMUNOTHERAPY FOR THE CURE OF ACUTE MYELOID LEUKEMIA WITH HIGH-RISK CYTOGENETICS 28
Natural killer cells as a therapeutic tool in mismatched transplantation 26
Regulatory T Cell Adoptive Immunotherapy Promotes B Cell Immunity after Haploidentical Transplantation 25
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia 22
Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation 21
Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation 21
REGULATORY T CELL ADOPTIVE IMMUNOTHERAPY PROMOTES B CELL IMMUNITY AFTER HAPLOIDENTICAL TRANSPLANTATION 19
How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia 18
ADOPTIVE IMMUNOTHERAPY WITH REGULATORY AND CONVENTIONAL T CELLS AFFORDS HIGH RATE OF CHRONIC GVHD/RELAPSE-FREE SURVIVAL IN ACUTE MYELOID LEUKEMIA AFTER MYELOABLATIVE HAPLOIDENTICAL TRANSPLANTATION 18
HLA-Matched Treg/Tcon Allogeneic Hematopoietic Cell Transplantation Is Safe and Ensures Remarkable Chronic GvHD/Leukemia Free Survival in High-Risk Leukemia Patients 17
Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation 16
TREG/TCON immunotherapy promotes HSC-derived B lymphopoiesis and boosts B cell immunity after haploidentical transplantation 14
null 11
Totale 1.808
Categoria #
all - tutte 9.862
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.862


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202077 0 0 0 0 0 1 8 0 20 32 10 6
2020/2021149 5 13 3 12 57 9 8 3 12 3 20 4
2021/2022273 1 69 2 6 18 3 4 77 3 20 34 36
2022/2023486 29 102 5 36 32 51 0 19 162 3 31 16
2023/2024381 14 32 7 10 0 11 77 2 24 15 88 101
2024/2025312 34 66 43 40 100 29 0 0 0 0 0 0
Totale 1.808